×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

²½³¤ÖÆÒ©×Ó¹«Ë¾×¢ÉäÓÃBC001Ò©ÎïÁÙ´²ÊÔÑé»ñÅú

2024-02-28
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20240228162701.jpg

Ò½ÏßÒ©ÎÅ

1. 2ÔÂ27ÈÕ£¬²½³¤ÖÆÒ©Ðû²¼Í¨¸æ³Æ£¬×Ó¹«Ë¾ËÄ´¨ãòÖݲ½ÓÀÉúÎïÖÆÒ©ÓÐÏÞ¹«Ë¾ÔÚÑÐÆ·ÖÖ¡°×¢ÉäÓÃBC001¡±ÐÂÔö˳Ӧ֢»ñÅúÁÙ´²£¬Ä⿪չµÄ˳Ӧ֢ΪBC001ÁªºÏPD-1µ¥¿¹ÖÎÁÆÍíÆÚ»ò×ªÒÆÐÔʵÌåÁö£¬°üÀ¨µ«²»ÏÞÓÚBC001ÁªºÏÐŵÏÀûµ¥¿¹¼ÓXELOXÒ»ÏßÖÎÁÆHER-2ÒõÐÔÍíÆÚ»ò×ªÒÆÐÔθ»òθʳ¹Ü½ÓÈÀ´¦ÏÙ°©¡£

2. 2ÔÂ26ÈÕ£¬ÓÉÖйú¿ÆÑ§ÔºÉϺ£Ò©ÎïÑо¿ËùÀîÑÇÆ½Ñо¿Ô±ÁìÏÎÑз¢µÄ¿¹Ö×Áö1ÀàÐÂÒ©HLN601Ö¬ÖÊÌ壬»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖµÄÁÙ´²ÊÔÑéÅú׼֪ͨÊ飬Ô޳ɿªÕ¹ÁÙ´²ÊÔÑé¡£

3. 2ÔÂ26ÈÕ£¬¼ªÏéµÂÐû²¼£¬ÃÀ¹úFDAÅú×¼Biktarvy£¨±È¿ËÌæÀ­Î¤50mg /¶÷ÇúËû±õ 200mg /ÌæÅµ¸£Î¤°¬À­·Ó°· 25mgƬ¼Á£¬B/F/TAF£©Ò»ÏîÐÂ˳Ӧ֢£¬ÓÃÓÚÖÎÁƲ¡¶¾ÔØÁ¿Êܵ½ÒÖÖÆÇÒÒÑÖª»òÒÉËÆ¾ßÓÐM184V/IÄÍÒ©ÐÔµÄHIVѬȾÕߣ¨PWH£©¡£

4. 2ÔÂ27ÈÕ£¬Ôƶ¥ÐÂÒ«Ðû²¼ÆäÒ»¿îÐÂÐÍ¡¢Í¬ÀàÊ×´´¡¢Ñ¡ÔñÐÔÃâÒßÂѰ×øÌåÒÖÖÆ¼Ázetomipzomib£¨ÔóÍÐ×ôÃ×£©»ñCDEÅú×¼ÔÚÖйúÆô¶¯ÖÎÁÆÔ˶¯ÐÔÀÇ´¯ÐÔÉöÑ×£¨LN£©µÄ2bÆÚPALIZADEÊÔÑé¡£

ͶÈÚÒ©ÊÂ

1. 2ÔÂ28ÈÕÐÂÎÅ£¬ÉϺ£¹âÉùÖÆÒ©ÓÐÏÞ¹«Ë¾ÀÖ³ÉÍê³É1ÒÚÔªÈËÃñ±ÒAÂÖÈÚ×Ê¡£±¾ÂÖÈÚ×ÊÓÉÖÐСÆóÒµÉú³¤»ù½ð£¨³É¶¼£©½»×Ó´´ÒµÍ¶×ʺÏ×ÊÆóÒµ£¨ÓÐÏÞºÏ×Ê£©ÁìͶ£¬ÈÚ×Ê¿î×Ó½«ÓÃÓÚÖÜÈ«¼ÓËÙ¹«Ë¾Ôڹ⶯Á¦ÖÎÁÆÁìÓòвúÆ·Ñз¢¼°Ê׿î²úÆ·ÉÌÒµ»¯¡£

¿Æ¼¼Ò©ÑÐ

1. ¿ËÈÕ£¬ÃÀ¹úʯϪ´óѧÑо¿ÍŶÓÔÚ Nature Communications ÔÓÖ¾½ÒÏþÁËÌâΪ ?Intestinal IL-22RA1 signaling regulates intrinsic and systemic lipid and glucose metabolism to alleviate obesity-associated disorders µÄÎÄÕ£¬ÆÊÎöÁË IL-22RA1 ÐźŴ«µ¼ÔÚµ÷¿Ø³¦µÀ¾úȺ´úлºÍ·ÊÅÖÏà¹Ø¼²²¡ÌÇÖ¬´úлÖеÄÒªº¦×÷Óá£

[1]Gaudino SJ, et al. Intestinal IL-22RA1 signaling regulates intrinsic and systemic lipid and glucose metabolism to alleviate obesity-associated disorders. Nat Commun. 2024 Feb 21;15(1):1597.

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿